## Abstract Ovarian tumors range from benign to aggressive malignant tumors, including an intermediate class referred to as borderline carcinoma. The prognosis of the disease is strongly dependent on tumor classification, where patients with borderline tumors have much better prognosis than patient
Expression of cell regulatory proteins in ovarian borderline tumors
β Scribed by Caroline van Haaften-Day; Peter Russell; Cinda M. Boyer; Billie-Jo M. Kerns; Jon R. Wiener; Debra N. Jensen; Robert C. Bast Jr.; Neville F. Hacker
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 616 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
Tumors of borderline malignancy are still a controversial subgroup of ovarian neoplasms. The expression of several cell regulatory proteins was studied to characterize the molecular phenotype of these tumors, and to compare them with their benign and malignant counterparts. METHODS. Specimens from 22 patients with tumors of borderline malignancy (1 1 serous and 11 mucinous tumors), 12 patients with benign tumors, and 16 patients with invasive ovarian carcinomas were evaluated for expression of epidermal growth factor receptor (EGFR), HER-2/neu, PTPlB, and p53 by immunohistochemical techniques.
π SIMILAR VOLUMES
Telomerase activity is involved in the maintenance of telomere length and is thought to be required for cellular immortality and oncogenesis. Three major subunits composing telomerase, human telomerase RNA (hTR), telomeraseassociated protein (TP1) and human telomerase catalytic subunit (hTERT), have
The immunoreactivity of monoclonal antibody (MoAb) B72.3 with ovarian serous tumors of borderline malignancy from 44 women who were pregnant, were on hormone medication containing a progestin, or were known to be in the secretory phase of the menstrual cycle, was compared with that of similar tumors
## BACKGROUND. The role of flow cytometric DNA analysis in predicting prognosis of patients with borderline malignant ovarian tumors has been controversial. ## METHODS. Fifty cases of patients with borderline malignant ovarian tumors were analyzed by histology and by flow cytometry on paraffin
among ethnic groups (based on ethnic group and country of birth) for the years 1985-1993.